Inflammatory Bowel Diseases · 2022 · 14 citations · 9 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationInflammationVaccinologyInflammatory Bowel DiseaseMrna Vaccine TechnologyVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyEffectiveness Against Symptomatic DiseaseFunctional Gastrointestinal SymptomsInflammatory Bowel Disease TherapyOverall Vaccine EffectivenessSars-cov-2 InfectionSymptom Frequency Measurement
BACKGROUND: The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown. METHODS: We compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD. RESULTS: The study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse. CONCLUSION: The frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.
9
Kimberly N. Weaver, Xian Zhang, Xiangfeng Dai et al. · Inflammatory Bowel Diseases · 2021 · 95 citations · Full text